Rahul K. Goyal

Rahul K. Goyal

Auto-generated profile, based on publicly available information

Rahul K. Goyal

Clinical Pharmacology AbbVie Inc. North Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
KNKunal Naik
Kunal Naik
RGRahul K. Goyal
Rahul K. Goyal
Luca FoschiniLuca Foschini
Luca Foschini
CCChoiwai Maggie Chak
Choiwai Maggie Chak
CTChristian Thielscher
Christian Thielscher
JGJogarao Gobburu
Jogarao Gobburu

24 September 2022 in Clinical and Translational Science
Verified
Journal Article
Open access
RGRahul K. Goyal
Rahul K. Goyal
SKShamir N. Kalaria
Shamir N. Kalaria
SMSusan L. McElroy
Susan L. McElroy
MGMathangi Gopalakrishnan
Mathangi Gopalakrishnan
Randomized, placebo‐controlled trials for binge eating disorder (BED) have revealed highly variable, and often marked, rates of short‐term placebo response. Several quantitative based analyses in patients with BED have inconsistently demonstrated which patient factors attribute to an increase in placebo response. The objective of this study is to utilize machine learning (ML) algorithms to identify moderators of placebo response in patients with BED. Data were pooled from 12 randomized placebo‐controlled trials evaluating different treatment options for BED. The final dataset consisted of 189 adults receiving placebo with complete information of baseline variables. Placebo responders were defined as patients experiencing ≥75% reduction in binge eating frequency (BEF) at study end point. Nine patient prerandomization variables were included as predictors. Patients were divided into training and testing subsets according to an 75%:25% distribution while preserving the proportion of placebo responders. All analysis was performed in the software Pumas 2.0. Gaussian Naïve Bayes algorithm showed the best cross‐validation accuracy (~64%) and was chosen as the final algorithm. Shapley analysis suggested that patients with low baseline BEF and anxiety status were strong moderators of placebo response. Upon applying the final algorithm on the test dataset, the resulting sensitivity was 88% and prediction accuracy was 72%. This is the first application of ML to identify moderators of placebo response in BED. The results of this analysis confirm previous findings of lesser baseline disease severity and adds that patients with no anxiety are more susceptible to placebo response.

26 July 2025 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
RGRahul K. Goyal
Rahul K. Goyal
BMBrady S. Moffett
Brady S. Moffett
KPKristine A. Parbuoni
Kristine A. Parbuoni
EHEmily Heil
Emily Heil
JGJogarao V. S. Gobburu
Jogarao V. S. Gobburu
Background and Objectives: The relative contribution of vancomycin exposure versus clinical factors to acute kidney injury (AKI) development in pediatric patients remains unclear. This study examined risk factors for AKI in pediatric patients receiving intravenous vancomycin therapy, with particular focus on elucidating the role of vancomycin concentrations and evaluating the safety implications of recent dosing guideline changes published in 2020.Methods: For this retrospective cohort study, Texas Children's Hospital database was queried between 2011 and 2019 for demographics, concomitant medications, vancomycin dosing and levels, serum creatinine, and mortality. AKI was defined using modified KDIGO criteria. Empirical Bayesian forecasting with a published population pharmacokinetic (PK) model generated rich PK profiles from sparse sampling data. Multivariate logistic regression was used to identify risk factors, and simulations were performed to evaluate 2020 guideline recommendations.Results: The final analysis dataset included 2318 vancomycin courses in 1714 unique patients. The typical dosing regimen in our dataset was 45 mg/kg/day every 8 h. AKI occurred in 18.9% of patients. Independent risk factors included lower age, ICU residence, vasopressor administration, concurrent piperacillin/tazobactam, and amphotericin B use. While vancomycin 24‐h area under the curve (AUC0–24) showed statistically significant association with AKI, the relationship was modest with minimal improvement in model performance compared to clinical factors alone. Simulations of 2020 guideline recommendations (60–80 mg/kg/day) predicted modest increases in AKI incidence from 19% to 21% when AUC was capped at 600 mg·h/L. However, given low mortality rate (1.9%) in our dataset despite only 43% of patients achieving the recommended AUC target of 400 mg·h/L, the clinical necessity for increased dosing remains questionable.Conclusions: Clinical factors are substantially more predictive of AKI than vancomycin exposure in pediatric patients. Given the questionable clinical necessity for increased dosing based on low mortality rates, prospective studies incorporating clinical efficacy endpoints are needed to establish optimal dosing strategies that balance therapeutic benefit with nephrotoxicity risk.

15 July 2026 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
SIShams Ismaeil
Shams Ismaeil
LSLucia Siovitz
Lucia Siovitz
RGRahul K. Goyal
Rahul K. Goyal
DEDoerthe Eckert
Doerthe Eckert
SSSven Stodtmann
Sven Stodtmann
HXHao Xiong
Hao Xiong
The US FDA recently accepted efficacy extrapolation from adult to pediatric patients for atypical antipsychotics in the treatment of schizophrenia (SCZ) and bipolar mania (BPM), considering the similarity in both disease and exposure‐response relationships for this class of drugs. Under this pharmacokinetic (PK)‐based efficacy extrapolation framework, pediatric population PK (popPK) models for cariprazine and its two active metabolites (desmethyl cariprazine [DCAR], didesmethyl cariprazine [DDCAR]) were developed by modifying previously validated adult popPK models and using pediatric PK data from two phase I trials. Covariate effects on PK parameters in legacy adult models were retained in the pediatric models, except that body weight effect on apparent elimination clearance and apparent volume of distribution of the central compartment were re‐estimated for all analytes. The final pediatric popPK models adequately described observed plasma concentrations of all three analytes with no significant bias over age or body weight in pediatric patients. Simulated total cariprazine (sum of cariprazine, DCAR and DDCAR) exposure at 1.5‐4.5 mg once daily (QD) in adolescents (13‐17 years) with SCZ and 3.0‐4.5 mg QD in children (10‐12 years) and adolescents with BPM resulted in predicted total cariprazine exposures within established efficacious ranges in adults with these conditions. Body weight did not meaningfully affect total cariprazine exposure and analyses did not support weight‐based dosing in 10‐12 year olds. This PK analysis supported the FDA approvals of cariprazine for the treatment of SCZ and BPM in pediatric patients by identifying efficacious doses for each indication based on efficacy extrapolation.